PFE Jan 2024 55.000 put
- LA Times
Column: A bogus new attack on COVID vaccines from Texas' least credible politician
Texas Attorney General Ken Paxton unveils a fact-free lawsuit questioning Pfizer's COVID vaccine, which has helped to save millions of people from hospitalization and death.
- Zacks
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
- GlobeNewswire
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the potential of vepdegestrant in combination with palbociclib (IBRANCE®) – – Tolerability generally consistent with the profile of palbociclib and what has been observed in other clinical trials of vepdegestrant– – Pending additional data and agreement with regulatory authorities, Arvinas and Pfizer pla
